A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.
It comes as a trial by Mounjaro manufacturer Eli Lilly – known as Surmount-5 – found patients on tirzepatide recorded a ...
The NHS spending watchdog has recommended Mounjaro – also known as tirzepatide and made by Eli Lilly – for those with a body ...
Final draft guidance published by Nice shows NHS England requested that Mounjaro is rolled out over a period of 12 years. The ...
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...
SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...
England’s National Health Service will begin rolling out Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro over the next few months, though the medication will initially be made available to ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.